Mammography Market

The secondary research process involved comprehensive analysis of imaging regulatory databases, peer-reviewed radiology journals, breast cancer screening publications, and authoritative medical imaging societies. Key sources included the US Food & Drug Administration (FDA) Mammography Quality Standards Act (MQSA) database, American College of Radiology (ACR) accreditation records, American Cancer Society (ACS) breast cancer statistics, Radiological Society of North America (RSNA) technical standards, European Society of Breast Imaging (EUSOBI) guidelines, International Agency for Research on Cancer (IARC) GLOBOCAN database, National Cancer Institute (NCI) Surveillance Epidemiology and End Results (SEER) Program, Centers for Disease Control and Prevention (CDC) National Program of Cancer Registries (NPCR), World Health Organization (WHO) cancer databases, Organisation for Economic Co-operation and Development (OECD) Health Statistics, National Institutes of Health (NIH) National Center for Biotechnology Information (NCBI/PubMed) for breast imaging studies, European Commission European Cancer Information System (ECIS), and national breast cancer screening program reports from key markets (NHS Breast Screening Programme UK, German Mammography Screening Program, Japan Cancer Society reports).

Breast cancer incidence data, screening program participation rates, MQSA-certified facility statistics, technology adoption trends, and regulatory compliance data for full-field digital mammography (FFDM), digital breast tomosynthesis (DBT), and computer-aided detection (CAD) systems were gathered using these sources.

Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. From mammography equipment manufacturers (digital X-ray, tomosynthesis, and imaging software developers), supply-side sources included CEOs, VPs of Imaging Product Development, regulatory affairs chiefs, and commercial directors. Board-certified radiologists who specialize in breast imaging, chiefs of radiology departments, medical physicists, medical directors of diagnostic centers, and procurement leaders from academic medical centers, hospitals, and specialty breast imaging centers comprised demand-side sources. Technology adoption curves were validated, FDA 510(k) clearance timelines for AI-enabled mammography systems were confirmed, and insights were gathered on equipment replacement cycles, service contract structures, reimbursement dynamics for 3D tomosynthesis vs. 2D mammography, and workflow integration patterns using primary research.

Primary Respondent Breakdown:

By Designation: C-level Primaries (32%), Director Level (30%), Others (38%)

By Region: North America (38%), Europe (28%), Asia-Pacific (25%), Rest of World (9%)

Through procedure volume analysis and equipment installation base tracing, the global market valuation was determined. The methodology comprised the following:

The identification of over 40 significant manufacturers in North America, Europe, Asia-Pacific, and Latin America, including analog equipment suppliers, tomosynthesis specialists, and providers of digital mammography systems.

Product mapping encompasses hybrid combination technologies, analog/film-screen systems, digital breast tomosynthesis (3D mammography), and full-field digital mammography (FFDM).

Analysis of annual revenues that are specific to mammography equipment portfolios, including hardware sales, software enhancements, and service/maintenance contracts, as reported and modeled

Manufacturers that account for 75-80% of the global market share in 2024 are included in the coverage.

Derive segment-specific valuations for screening mammography versus diagnostic mammography applications through extrapolation using bottom-up (installed base × equipment ASP by country × replacement cycles plus recurring service revenue) and top-down (manufacturer revenue validation against screening program procurement data) approaches.